Status:
COMPLETED
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
Lead Sponsor:
Medy-Tox
Conditions:
Hyperhidrosis Primary Focal Axilla
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.
Eligibility Criteria
Inclusion
- adult patients aged from 20 to 65, with persistent bilateral primary axillary hyperhidrosis
Exclusion
- those who have secondary hyperhidrosis
- those who have systemic neuromuscular junction disorders
- women who are pregnant or lactating
Key Trial Info
Start Date :
August 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 17 2019
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT03760198
Start Date
August 3 2018
End Date
September 17 2019
Last Update
July 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic University St. Paul Hospital
Seoul, Dongdaemun-gu, South Korea, 130-709